| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 143 | 1,031 | 361 | - |
| Research and development | 90,464 | 80,301 | 76,240 | 61,905 |
| Selling, general and administrative | 52,265 | 49,842 | 35,526 | 25,892 |
| Total operating expenses | 142,729 | 130,143 | 111,766 | 87,797 |
| Loss from operations | -142,586 | -129,112 | -111,405 | -87,797 |
| Other income (expense), net | - | 20 | -203 | -37 |
| Interest income | 12,544 | 13,455 | 14,834 | 11,006 |
| Other expense, net | -49 | - | - | - |
| Total other income, net | 12,495 | 13,475 | 14,631 | 10,969 |
| Loss before equity method investment | -130,091 | 115,637 | 96,774 | 76,828 |
| Loss on equity method investment | 0 | - | - | - |
| Net loss | -130,091 | -115,637 | -96,774 | -76,828 |
| Unrealized gain on investment securities | 594 | -347 | 1,033 | 2,228 |
| Unrealized loss on foreign currency | -21 | -34 | 6 | - |
| Total other comprehensive income | 573 | -381 | 1,039 | - |
| Comprehensive loss | -129,518 | -116,018 | -95,735 | -74,600 |
| Net loss per share - basic (in dollar per share) | -1.38 | -1.23 | -1.04 | -0.96 |
| Net loss per share - diluted (in dollar per share) | -1.38 | -1.23 | -1.04 | -0.96 |
| Weighted average shares - basic (in shares) | 94,215,000 | 93,791,000 | 93,102,000 | 80,091,000 |
| Weighted average shares - diluted (in shares) | 94,215,000 | 93,791,000 | 93,102,000 | 80,091,000 |
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)